Classification of current anticancer immunotherapies

摘要: During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to robust clinical reality. Many immunotherapeutic regimens are now approved by US Food and Drug Administration European Medicines Agency for use in cancer patients, many others being investigated as standalone interventions or combined with conventional treatments studies. Immunotherapies may be subdivided into “passive” “active” based on their ability engage host immune system against cancer. Since activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies system, this classification does not properly reflect complexity drug-host-tumor interaction. Alternatively, can classified according antigen specificity. While some immunotherapies specifically target one (or few) defined tumor-associated antigen(s), operate relatively non-specific manner boost natural therapy-elicited responses unknown often broad Here, we propose critical, integrated discuss relevance these approaches.